(Q44997898)

8 December 2017

title

Immunological checkpoint inhibitors enter adolescence (English)

1 reference

8 December 2017

0 references

1

1 reference

8 December 2017

publication date

11 September 2013

1 reference

Lancet Oncology Commission

8 December 2017

published in

1 reference

8 December 2017

volume

14

1 reference

8 December 2017

issue

11

1 reference

8 December 2017

page(s)

1035-1037

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

Ipilimumab: first global approval

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

T-cell regulation by CD28 and CTLA-4.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

Phase I/II trial of tremelimumab in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970401-7

7 January 2021

10.1016/S1470-2045(13)70401-7

Identifiers

DOI

1 reference

8 December 2017

1 reference